WO2001090079A3 - Neue carbamate und harnstoffe, ihre herstellung und verwendung als endothelin-rezeptorantagonisten - Google Patents

Neue carbamate und harnstoffe, ihre herstellung und verwendung als endothelin-rezeptorantagonisten Download PDF

Info

Publication number
WO2001090079A3
WO2001090079A3 PCT/EP2001/005742 EP0105742W WO0190079A3 WO 2001090079 A3 WO2001090079 A3 WO 2001090079A3 EP 0105742 W EP0105742 W EP 0105742W WO 0190079 A3 WO0190079 A3 WO 0190079A3
Authority
WO
WIPO (PCT)
Prior art keywords
production
receptor antagonists
carbamides
endothelin receptor
novel carbamates
Prior art date
Application number
PCT/EP2001/005742
Other languages
English (en)
French (fr)
Other versions
WO2001090079A2 (de
Inventor
Wilhelm Amberg
Georg Kettschau
Original Assignee
Basf Ag
Wilhelm Amberg
Georg Kettschau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag, Wilhelm Amberg, Georg Kettschau filed Critical Basf Ag
Priority to US10/296,443 priority Critical patent/US20040034076A1/en
Priority to AU2001265995A priority patent/AU2001265995A1/en
Priority to EP01943411A priority patent/EP1286973A2/de
Priority to JP2001586268A priority patent/JP2003534329A/ja
Priority to CA002410304A priority patent/CA2410304A1/en
Priority to MXPA02011512A priority patent/MXPA02011512A/es
Publication of WO2001090079A2 publication Critical patent/WO2001090079A2/de
Publication of WO2001090079A3 publication Critical patent/WO2001090079A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die vorliegende Erfindung betrifft Carbamat- und Harnstoffderivate der Formel (I), wobei die Substituenten die in der Beschreibung erläuterte Bedeutung haben, sowie ihre Herstellung und Verwendung als Endothelin-Rezeptorantagonisten.
PCT/EP2001/005742 2000-05-25 2001-05-18 Neue carbamate und harnstoffe, ihre herstellung und verwendung als endothelin-rezeptorantagonisten WO2001090079A2 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US10/296,443 US20040034076A1 (en) 2000-05-25 2001-05-18 Novel carbamates and carbamides, production and use thereof as endothelin receptor antagonists
AU2001265995A AU2001265995A1 (en) 2000-05-25 2001-05-18 Novel carbamates and carbamides, production and use thereof as endothelin receptor antagonists
EP01943411A EP1286973A2 (de) 2000-05-25 2001-05-18 Neue carbamate und harnstoffe, ihre herstellung und verwendung als endothelin-rezeptorantagonisten
JP2001586268A JP2003534329A (ja) 2000-05-25 2001-05-18 新規のカルバメート及び尿素、その製造及びエンドセリン受容体アンタゴニストとしての使用
CA002410304A CA2410304A1 (en) 2000-05-25 2001-05-18 Novel carbamates and ureas production and use thereof as endothelin receptor antagonists
MXPA02011512A MXPA02011512A (es) 2000-05-25 2001-05-18 Carbamatos y carbamidas novedosos, su produccion y uso como antagonistas de los receptores para endotelina.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10025728.3 2000-05-25
DE10025728A DE10025728A1 (de) 2000-05-25 2000-05-25 Neue Carbamate und Harnstoffe, ihre Herstellung und Verwendung als Endothelin-Rezeptorantagonisten

Publications (2)

Publication Number Publication Date
WO2001090079A2 WO2001090079A2 (de) 2001-11-29
WO2001090079A3 true WO2001090079A3 (de) 2002-04-04

Family

ID=7643406

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/005742 WO2001090079A2 (de) 2000-05-25 2001-05-18 Neue carbamate und harnstoffe, ihre herstellung und verwendung als endothelin-rezeptorantagonisten

Country Status (8)

Country Link
US (1) US20040034076A1 (de)
EP (1) EP1286973A2 (de)
JP (1) JP2003534329A (de)
AU (1) AU2001265995A1 (de)
CA (1) CA2410304A1 (de)
DE (1) DE10025728A1 (de)
MX (1) MXPA02011512A (de)
WO (1) WO2001090079A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790770B2 (en) 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007266A1 (de) * 1993-09-04 1995-03-16 Basf Aktiengesellschaft Substituierte milchsäurederivate mit einem n-organischen rest in beta-position, deren herstellung und deren verwendung als herbizide und antidote
WO1997038980A1 (de) * 1996-04-12 1997-10-23 Basf Aktiengesellschaft Neue carbonsäurederivate, ihre herstellung und verwendung
WO1999023078A2 (de) * 1997-10-31 1999-05-14 Basf Aktiengesellschaft Neue carbonsäurederivate, die amidseitenketten tragen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007266A1 (de) * 1993-09-04 1995-03-16 Basf Aktiengesellschaft Substituierte milchsäurederivate mit einem n-organischen rest in beta-position, deren herstellung und deren verwendung als herbizide und antidote
WO1997038980A1 (de) * 1996-04-12 1997-10-23 Basf Aktiengesellschaft Neue carbonsäurederivate, ihre herstellung und verwendung
WO1999023078A2 (de) * 1997-10-31 1999-05-14 Basf Aktiengesellschaft Neue carbonsäurederivate, die amidseitenketten tragen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten

Also Published As

Publication number Publication date
MXPA02011512A (es) 2003-06-30
WO2001090079A2 (de) 2001-11-29
DE10025728A1 (de) 2001-11-29
EP1286973A2 (de) 2003-03-05
US20040034076A1 (en) 2004-02-19
CA2410304A1 (en) 2002-11-22
JP2003534329A (ja) 2003-11-18
AU2001265995A1 (en) 2001-12-03

Similar Documents

Publication Publication Date Title
WO2003093269A3 (de) Substituierte pyrazolo-pyrimidin-4-one
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
MXPA03008714A (es) Polimeros secuenciados y composiciones cosmeticas que comprenden tales polimeros.
GB0305704D0 (en) Radiofluorination methods
EG25011A (en) Amino-piperidin-1-yl-xanthines, the production thereof and the use of the same as medicaments.
DE60236102D1 (en) 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren
WO2001023390A3 (de) Azepinoindol-derivate, deren herstellung und anwendung
WO2004018451A8 (en) Pyridazinone-derivatives as pde4 inhibitors
IL168102A0 (en) Chk-, pdk-and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
PL361355A1 (en) Phenylglycine derivatives
AU2003293757A1 (en) Novel substituted imidazo-pyridinones and imidazo-pyridazeiones, the production and use thereof as medicaments
WO2002057242A3 (en) Urea derivatives as integrin alpha 4 antagonists
SE9702773D0 (sv) Novel compounds
RS81904A (en) Phosphate prodrugs of fluorooxindoles
MY133969A (en) Indoloquinazolinones
WO2004035800A3 (en) Intermediate cefdinir salts
MY136297A (en) Piperazine derivatives having sst1 antagonistic activity
AU2003248647A1 (en) Stereoselective synthesis of 1,2-disubstituted cycloalkyls
WO2001009122A3 (en) Serotonergic benzofurans
WO1999037291A3 (de) Verwendung von substituierten sulfonamiden als antivirale mittel und neue stoffe
WO2001090079A3 (de) Neue carbamate und harnstoffe, ihre herstellung und verwendung als endothelin-rezeptorantagonisten
TR199903159T2 (xx) Yeni �-Amino ve �-Azido karbonik asit t�revleri.
WO2001010861A3 (de) Substituierte heterocyclyl-2h-chromene
WO2001046128A3 (en) Tryptase inhibitors
AU2002368487A1 (en) Substituted 1,4-di-piperidin-4-yl-piperazine derivatives and their use as tachykinin antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/011512

Country of ref document: MX

Ref document number: 2410304

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001943411

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001943411

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10296443

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2001943411

Country of ref document: EP